AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05636293 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gluten
Description: 10g of gluten
Study NCT05987241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05987241 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05987241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05987241 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Given IV
Study NCT06017414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Systemic Psychotherapy-informed Growth Path
Description: A self-guided program lasting 5 weeks on the 7 Cups platform. The self-help intervention aims to support members to explore their relationships, situations, and goals.
Study NCT06017414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Systemic Psychotherapy-informed Listener Training
Description: A self-guided program lasting 5 weeks on the 7 Cups platform. The self-help intervention encourages listeners to explore their relationships, situations, and goals and think about how they would support members working through their own relationships, situations, and goals.
Study NCT06122194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: PF-07817883
Description: PF-07817883 tablet
Study NCT06395649 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Classical rTMS to M1
Description: The rTMS intervention consists of 10-Hz rTMS. Thirty trains of ten seconds with an interval of twenty seconds between trains will be delivered, as traditionally performed. Each train includes 100 pulses, and the total number of pulses will be 3,000 given in 15 minutes.
Study NCT06395649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS to the High connectivity target
Description: The rTMS intervention consists of 10-Hz rTMS. Thirty trains of ten seconds will be delivered with an interval of twenty seconds between trains. Each train includes 100 pulses, and the total number of pulses will be 3,000 given in 15 minutes. The rTMS will be delivered to the target, showing the highest connectivity.
Study NCT06395649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS to the low connectivity target
Description: The rTMS intervention consists of 10-Hz rTMS. Thirty trains of ten seconds with an interval of twenty seconds between trains will be delivered. Each train includes 100 pulses, and the total number of pulses will be 3,000 given in 15 minutes. The rTMS will be delivered to the target, showing the lowest connectivity.
Study NCT04856085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection
Study NCT06395649 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Sham stimulation was carried out with a sham coil of identical size, color, and shape, emitting a sound similar to that emitted by the active coil.
Study NCT06096623 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly Survey
Description: Subjects will respond to Electronic patient-reported outcome (ePRO) every week for 8 weeks.
Study NCT05026983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO
Study NCT05026983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Given PO
Study NCT05026983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06547151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMOR-1
Description: Investigational arm: Tablets containing 250mg elemental calcium from Amorphous Calcium Carbonate (ACC).
Study NCT06547151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crystalline Calcium Carbonate
Description: Control arm: Crystalline Calcium Carbonate (CCC) oral tablet contains 500 mg elemental calcium.
Study NCT05655702 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Community based TB intervention
Description: * 3 bi-annual RDSS (RDSS1, 2 and 3), for TB screening~* A PWID-specific Information and communication (I\&C) TB module to improve PWID awareness about TB,~* Peer group support to facilitate TB treatment initiation and retention,~* Implementation of a peer support contact tracing and screening for active TB in contacts.
Study NCT05338268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for Loneliness
Description: CBT delivered over the course of 8, \~45 minute sessions delivered via telehealth.
Study NCT05338268 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Health education provides information on the importance and benefits of and guidelines for living a healthy lifestyle.
Study NCT06104605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Institutional interventions
Description: Intervention will include, but not be limited to, the following: adding a referral option to chiropractic care in the electronic health record (EHR), optimizing referral option, e.g., creating a list of preferred providers. Additional strategies may be added depending on community health center staff engagement prior to implementation.
Study NCT06104605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PCPs interventions
Description: Two one-hour interactive grand rounds/lunch seminars that allow for inter-professional learning for PCPs with optional continuing education credits for PCPs.~Short teaching cases involving clinical vignettes developed with local doctors of chiropractic (DCs), information about DCs (e.g., evidence-base for treatments), and logistics of the referral process (e.g., geographic location of community-based DCs who accept Medicaid) sent to participating providers unable to attend the seminars. Additional strategies may be added depending on primary care provider engagement prior to implementation.
Study NCT06104605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient interventions
Description: Printed and electronic educational materials (e.g., brochures) written at a sixth grade reading level in English and Spanish that present chiropractic as a safe and effective evidence-based treatment for LBP. These materials will be written, reviewed, and revised by the researchers with CHC patient input. Additional strategies may be added depending on patient engagement prior to implementation.
Study NCT05966064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab 120 Mg/1.7 Ml Inj
Description: Denosumab randomized at baseline and after 3 months at 6 and 9 months in case of open label
Study NCT05966064 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo randomized at baseline and after 3 months
Study NCT05755256 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: After randomization, participants will consume the probiotic for 12 weeks.
Study NCT05755256 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After randomization, participants will consume the placebo for 12 weeks.
Study NCT05575219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine (without protocolized initiation)
Description: Participants will be observed for dexmedetomidine withdrawal and clonidine will be started at clinician discretion.
Study NCT05575219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine (protocolized initiation)
Description: * Observe participants without initiating clonidine with dexmedetomidine infusion time of 72-119 hours. To wean off dexmedetomidine, decrease the infusion by 25% of the starting dose every 6 hours.~* Begin clonidine at 1 mcg/kg enterally every 6 hours for participants with dexmedetomidine infusion time of 120-144 hours.~* Begin clonidine at 1.5 mcg/kg enterally every 6 hours for participants with dexmedetomidine infusion times of 145-167 hours.~* Begin clonidine at 2 mcg/kg enterally every 6 hours for participants with dexmedetomidine infusion time of >/= 168 hours or with infusion time of 120-167 hours at doses >/= 1.1 mcg/kg/min.~* If clonidine is started decrease the dexmedetomidine infusion by 25% of the starting dose 1 hour after each dose of clonidine until off (wean every 6 hours).
Study NCT05496036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 400mg IV
Study NCT05868486 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05868486 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic Testing for Cancer Risk
Description: Undergo germline testing
Study NCT05868486 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liquid Biopsy
Description: Undergo liquid biopsy testing
Study NCT05868486 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging of the Whole Body without Contrast
Description: Undergo whole body MRI without contrast
Study NCT05868486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete surveys
Study NCT06466135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WAL0921
Description: Investigational drug WAL0921 Participants receive an intravenous infusion of WAL0921 investigational drug once every 2 weeks for 7 total infusions.
Study NCT06466135 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo product Participants receive an intravenous infusion of placebo once every 2 weeks for 7 total infusions.
Study NCT05341557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-371153
Description: Subjects will receive BPI-371153 until disease progression
Study NCT06021782 — intervention group
Intervention type: OTHER
Intervention: All subjects-Observation
Description: The sonographer or study team member will scan the lateral vaginal walls (Left and right) directing the probe slightly caudad in direction of the ischial spine (IS). The IS is very echogenic and easily identifiable (bony landmark). Anatomically, the pudendal nerve courses underneath the IS and travels with the vascular bundle of the pudendal artery and pudendal vein. The artery and the vein will be identified using color flow Doppler at the time of the scan. These landmarks, IS, pudendal artery and vein will serve as the basis for the identification of the pudendal nerve.
Study NCT06545682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib + Pembrolizumab
Description: Given by mouth (PO) Given by vein (IV)
Study NCT06543810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hula for Parkinson's
Description: A feasibility study for a Hula program for Parkinson's Disease patients.
Study NCT06184568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI362
Description: Once-weekly injections of gradually increased doses of IBI362, subcutaneously (SC)，starting dose is IBI362 2.0 mg, continuous After 4 weeks of administration, increase to IBI362 4.0 mg. After 4 weeks of continuous administration, continue to increase to IBI362.
Study NCT04726280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% Injectable Solution
Description: 10 ml extrafascial interscalene brachial plexus block
Study NCT04726280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.75% Injectable Solution
Description: 20 ml extrafascial interscalene brachial plexus block
Study NCT06503016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phosphocreatine
Description: Administration of Phosphocreatine
Study NCT06503016 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution of NaCl 0.9%
Study NCT05943535 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered QID
Study NCT05943535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Treprostinil
Description: Inhaled treprostinil (6 mcg/breath) administered QID
Study NCT05943535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treprostinil Ultrasonic Nebulizer
Description: Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
Study NCT05943535 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Treprostinil Ultrasonic Nebulizer
Description: Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
Study NCT05834712 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile platform or not mobile platform
Description: Intervention using WeChat
Study NCT05834712 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mobile platform or not mobile platform
Description: Intervention using WeChat
Study NCT05655325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based walking exercise
Description: A 6-month partially supervised walking exercise program using a tapered approach.Participants will begin exercise (walking) at a relatively low intensity and progress to moderate intensity. Intensity will start at 40% and progress as tolerated up to 60-70%. Rating of perceived exertion of 12-14 (fairly light to moderate) will be used to aid intensity (Rating of perceived exertion 6-20 scale). This is an accepted method for achieving desired exercise intensity. Participants will progress over time to exercise 3-4/week for 30-45 minutes. The exercise program may need to be adjusted for (e.g. 10 minutes of exercise 3 times), to achieve the minimum exercise dose of 30 minutes. This will be determined for each individual participants as needed.
Study NCT05655325 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Attention control
Description: Health education and stretching
Study NCT05304377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELVN-001
Description: orally once or twice daily
Study NCT05841394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40mg
Description: 40 mg i.v. twice daily (q12h)
Study NCT05841394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole Sodium
Description: 10 mg i.v. once daily, 20 mg i.v. in the first day.
Study NCT05153239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 75 mg/m² intravenously Days 1 \& 8 q3wk
Study NCT05153239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Lurbinectedin 3.2 mg/m² will be administered intravenously on Day 1 q3wk
Study NCT05153239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: For patients aged \<70 years: irinotecan 350 mg/m² intravenously Day 1 q3wk For patients aged ≥70 years: irinotecan 300 mg/m² intravenously Day 1 q3wk
Study NCT05153239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Topotecan 2.3 mg/m² oral or 1.5 mg/m² intravenously Days 1-5 q3wk
Study NCT05153239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Lurbinectedin 2.0 mg/m² will be administered intravenously on Day 1 q3wk
Study NCT05374603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: Savolitinib combine with Durvalumab
Study NCT05374603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: savolitinib plus durvalumab
Study NCT06184568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Once-weekly injections of gradually increased doses of Semaglutide, subcutaneously (SC)，starting dose is semaglutide 0.25mg, after 4 weeks of continuous administration, increase to semaglutide 0.5mg, after 4 weeks of continuous administration, continue Upgrade to semaglutide 1.0 mg for 24 weeks.
Study NCT05917288 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab will be administered
Study NCT05917288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of care will be administered
Study NCT05396924 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectal temperature measurement
Description: Patients will be operated in the same operating room and at the same room temperature with the same type/amount of covering and body warming. At the start of the surgical procedure, a probe inserted into the rectal mucosa will measure the patient's body temperature every 15 minutes. In addition, the temperature of the patients will be measured from their temporal regions with a contactless thermometer. The data obtained will be analyzed by a blinded researcher. Mean body temperatures measured from 2 different locations (temporal region and rectal mucosa) between the groups will be compared, and the probability of detecting early local and later general hypothermia from the rectal mucosa will be examined
Study NCT05396924 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Temporal temperature measurement
Description: Patients will be operated in the same operating room and at the same room temperature with the same type/amount of covering and body warming. At the start of the surgical procedure, a probe inserted into the rectal mucosa will measure the patient's body temperature every 15 minutes. In addition, the temperature of the patients will be measured from their temporal regions with a contactless thermometer. The data obtained will be analyzed by a blinded researcher. Mean body temperatures measured from 2 different locations (temporal region and rectal mucosa) between the groups will be compared, and the probability of detecting early local and later general hypothermia from the rectal mucosa will be examined
Study NCT04915170 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: The device incorporate a unidirectional valve independent of flow to guarantee constant resistance and included a specific pressure setting (in cm H2O)
Study NCT06560463 — intervention group
Intervention type: DEVICE
Intervention: Access to Dexcom G7 CGM Data
Description: Eligible patients will undergo Continuous Glucose Monitoring using the Dexcom G7
Study NCT03843190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Take of Pounds Sensibly (TOPS)
Description: Dietician-facilitated classes
Study NCT03843190 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist Control
Description: At end of study, offered peer-led classes to attend.
Study NCT05161715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obicetrapib
Description: 10mg obicetrapib
Study NCT06646016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxsalen
Description: Sterile solution used in conjunction with photopheresis procedure.
Study NCT06646016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Infliximab will be administered intravenously.
Study NCT06646016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vedolizumab
Description: Vedolizumab will be administered intravenously.
Study NCT06151574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zongertinib
Description: zongertinib
Study NCT06151574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pembrolizumab
Description: pembrolizumab
Study NCT06151574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: platinum-pemetrexed chemotherapy
Study NCT06151574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: platinum-pemetrexed chemotherapy
Study NCT06151574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: platinum-pemetrexed chemotherapy
Study NCT06386094 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiographic assessment
Description: M mode, cross sectional and pulsed wave Doppler Echocardiographic examinations will be performed using a with a 2.5 MHz wide angle phased array transducer. Patients will be laid in left lateral position and examined in standard parasternal long and short axis and apical views. Short axis recordings will be performed at the level of the papillary muscles. M mode tracings will be recorded at the level of the papillary muscles and the aortic valves, with 2 -D guidance. LV wall thickness and cavity diameters will be measured by M mode, through the largest diameter of the ventricle, if possible, both in diastole and systole. Using the cross-sectional images as a guide, the M mode tracing of the left ventricle will obtained to calculate measurements according to the recommendations of American Society of Echocardiography.
Study NCT06646432 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tunnel with connective tissue graft and injectable platelet rich fibrin
Description: Tunnel with connective tissue graft and injectable platelet rich fibrin
Study NCT06646432 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tunnel with connective tissue graft only
Description: Tunnel technique with connective tossue graft only without injectable platelet rich fibrin
Study NCT05220319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: 250 mg Methylprednisolone made up with 100 ml NaCl0,9% as an IV injection at the induction of anaesthesia but before surgery. If CPB is required an additional dose in 100 ml will be given.
Study NCT05767034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Description: Taken subcutaneously every 4 weeks until Week 48 in combination with a 24-week prednisone taper regimen